Mergers & acquisitions

Amneal and Impax are combining into a new entity that is expected to have the fifth largest generics business in the United States.
The approval has made Flexion an even bigger target of acquisition rumors.
In a filing with the SEC,Orexigen indicated that it may not have enough funds to continue operating.
PRESS RELEASES